Q2 2023

Filed Aug 21, 2023 · 10-Q · 52 days after period end · 0001493152-23-029606

Q2 2023 · 10-Q

Revenue—

Net Income

-$22.18M

N/M vs Q2 2022

EPS Diluted

-$0.18

no prior Q2 2022 on file

Operating Income-$2,184,466—

Operating Cash Flowderived-$2,217,519N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021
Net Income	-$22.18M	$207.00K	-$11.30K
EPS Diluted	-$0.18	—	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Tevogen Inc. · CIK 1860871 · Engraved from SEC EDGAR